[Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP].

To preliminarily observe the antiviral effect of receptor-targeted drug, the Lactosaminated Human Serum Albumin Arabinoside Adenine Monophosphate (L-HSA-Ara-AMP), 10 patients with chronic type B hepatitis (HBsAg, HbeAg/HBV DNA positive) were treated with this drug for 5 days. The daily dose of L-HSA-Ara-AMP was 35 mg/Kg (containing 1.5 mg Ara-AMP), whereas the usual daily dose of free Ara-AMP is 10 mg/Kg. In 10 patients treated, three patients' HBeAg became negative and six patients' HBeAg titer fell. Anti-HBc IgM all became negative in 4 anti-HBc IgM positive patients. In 8 HBV DNA positive patients, four patients' HBV DNA became negative and the other four patients' HBV DNA decreased. HBsAg remained positive in all of the ten patients. No adverse effects were observed. The results showed that L-HSA-Ara-AMP inhibits HBV as effective as free Ara-AMP, but at a daily dose 6.7 times lower than free Ara-AMP.